Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2019

View Archived Issues

Alpha-synuclein and autophagy

Hypothermia activates hypoxia protein, benefits metabolism

First green tea-triggered genetic control system reported

Positive clinical data presented for omburtamab

CLDN6 identified as a tumor-promoting gene in gastric cancer

Data presented for the oral, clinical stage, class I specific HDACi OKI-179

Kinesins are involved in the pathophysiology of genetically undiagnosed Rett syndrome

Adenoviral gene therapy rescues eukaryotic translation elongation factor 1 alpha 2 knockout in mice

New GABA-A receptor alpha 5 PAM with pro-cognitive, anxiolytic and antidepressant effects in mice

First patient dosed in phase I/II study of LNS-8801 in patients with advanced cancer

Themis Bioscience and CEPI initiate phase I study of Lassa fever vaccine candidate

FTO variant rs9939609 as a new genetic biomarker in Crohn's disease

FORMA Therapeutics discloses new histone deacetylase 8 inhibitors

Dihydroorotate dehydrogenase inhibitors discovered at Bayer

East China University of Science and Technology patents dihydroorotate dehydrogenase inhibitors

Dalian Institute of Chemical Physics CAS patents muscarinic M1/ M3 receptor antagonists

Proline derivatives identified at Qingdao Marine Biomedical Research Institute

Dosing begins in first-in-human study of UCARTCS1 for relapsed/refractory multiple myeloma

European Commission approves Dupixent for chronic rhinosinusitis with nasal polyposis

FDA places partial hold on AVXS-101 intrathecal clinical trials

CytomX initiates phase II study of CX-072 with ipilimumab in relapsed or refractory melanoma

miRagen Therapeutics reports on miR-29 programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 17, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...